Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Immunotherapy combo improves ORR, PFS in PD-L1+ NSCLC

Publish date:: June 22, 2020

Key clinical point: Adding tiragolumab to atezolizumab as first-line treatment improves outcomes in PD-L1–positive non–small cell lung cancer.

Major finding: The overall response rate was 37% with tiragolumab/atezolizumab and 21% with placebo/atezolizumab. The median progression-free survival was 5.6 months and 3.9 months, respectively.

Study details: The phase 2 CITYSCAPE study of 135 patients.

Disclosures: The study was sponsored by Genentech. The presenter disclosed relationships with Genentech and numerous other companies.

Citation:

Rodriguez-Abreu et al. ASCO 2020, Abstract 9503.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,